High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
69.40M
-8.08%
-0.130
-134.21%
71.08M
-5.2%
-1.210
-48.07%
70.58M
+8.11%
0.280
-117.5%
Estimates Revision
The market is revising No Change the revenue expectations for Galapagos NV (GLPG) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by -4.77%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-37.08%
In Past 3 Month
Stock Price
Go Down
-4.77%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 30.50 USD with a low forecast of 22.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
2 Sell
Hold
Current: 31.770
Low
22.00
Averages
30.50
High
40.00
Current: 31.770
Low
22.00
Averages
30.50
High
40.00
Bernstein
Market Perform
initiated
€27.90
2025-11-26
Reason
Bernstein
Price Target
€27.90
2025-11-26
initiated
Market Perform
Reason
Bernstein initiated coverage of Galapagos with a Market Perform rating and EUR 27.90 price target. The firm says the company has transformed itself from a biotech with a cell therapy pipeline into an investment company that seeks to build biotech businesses. Galapagos has undergone a "complete reset," the analyst tells investors in a research note.
RBC Capital
Sector Perform
maintain
$28 -> $32
2025-11-07
Reason
RBC Capital
Price Target
$28 -> $32
2025-11-07
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Galapagos (GLPG) to $32 from $28 and keeps a Sector Perform rating on the shares. The firm is citing better than expected cost/interest structure, along with increased Gilead (GILD) amenability to recast Galapagos economics, the analyst tells investors in a research note.
RBC Capital
Brian Abrahams
Sector Perform
maintain
$27 -> $28
2025-10-22
Reason
RBC Capital
Brian Abrahams
Price Target
$27 -> $28
2025-10-22
maintain
Sector Perform
Reason
RBC Capital analyst Brian Abrahams raised the firm's price target on Galapagos (GLPG) to $28 from $27 and keeps a Sector Perform rating on the shares. The formal wind-down of the CAR-T program is not entirely surprising, but forces a re-think of how to appropriately value a company with a significant balance sheet and a biopharma-experienced leadership team but which is effectively a cash shell with unknown BD outcomes and some encumbrance from the Gilead (GILD) collaboration, the analyst tells investors in a research note.
Leerink
Market Perform -> Outperform
upgrade
$40
2025-10-21
Reason
Leerink
Price Target
$40
2025-10-21
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Galapagos to Outperform from Market Perform with a $40 price target.
Leerink
Faisal Khurshid
Market Perform -> Outperform
upgrade
$29 -> $40
2025-10-21
Reason
Leerink
Faisal Khurshid
Price Target
$29 -> $40
2025-10-21
upgrade
Market Perform -> Outperform
Reason
Leerink analyst Faisal Khurshid upgraded Galapagos to Outperform from Market Perform with a price target of $40, up from $29. The firm has "renewed confidence" in the company's plans to ease spending and pursue reasonable business development following the announcement that it would wind down its cell therapy business. In addition, Galapagos shares continue to trade at "deeply negative" enterprise value, the analyst tells investors in a research note. Leerink believes the company's new management has proven capable of "making tough but needed decisions." The firm sees the stock trading up towards Galapagos' cash balance as the market gains confidence in management.
Deutsche Bank
Hold
to
Sell
downgrade
€19
2025-08-05
Reason
Deutsche Bank
Price Target
€19
2025-08-05
downgrade
Hold
to
Sell
Reason
Deutsche Bank downgraded Galapagos to Sell from Hold with a EUR 19 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Galapagos NV (GLPG.O) is -41.66, compared to its 5-year average forward P/E of -6.17. For a more detailed relative valuation and DCF analysis to assess Galapagos NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.17
Current PE
-41.66
Overvalued PE
92.73
Undervalued PE
-105.07
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
10.84
Current EV/EBITDA
5.75
Overvalued EV/EBITDA
17.61
Undervalued EV/EBITDA
4.08
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
7.00
Current PS
6.32
Overvalued PS
8.62
Undervalued PS
5.39
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
GLPG News & Events
Events Timeline
(ET)
2025-10-21
05:52:20
Galapagos plans to cease operations in its cell therapy division.
2025-10-01 (ET)
2025-10-01
16:03:39
Galapagos Offers Update on Strategic Options for Cell Therapy Division
2025-08-06 (ET)
2025-08-06
05:28:08
Galapagos granted RMAT designation to GLPG5101 by FDA
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/18d34b6c6861993c76bc9c529b437a63297b13d48c42719a9fa87a7817fccb2c.jpg)
Preview
6.5
11-26NewsfilterBank of America Increases Galapagos Voting Rights to 5.26%
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b9ab60b5e4f8947ab537762412fc14e69ca8846ab2709020a2253d95714c624b.jpg)
Preview
4.0
10-29NASDAQ.COMGLPG Surpasses Average Analyst Price Target
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/fdb1b91b8ca178f36a37e417ead9cac31b8ca5d48df9dfde9293f2646a9b194c.jpg)
Preview
4.0
10-22NASDAQ.COMLeerink Partners Raises Rating on Galapagos NV - Depositary Receipt (GLPG)
Sign Up For More News
People Also Watch
FAQ
What is Galapagos NV (GLPG) stock price today?
What is Galapagos NV (GLPG)'s business?
What is the price predicton of GLPG Stock?
What is Galapagos NV (GLPG)'s revenue for the last quarter?
What is Galapagos NV (GLPG)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Galapagos NV (GLPG)'s fundamentals?
How many employees does Galapagos NV (GLPG). have?